Nerve damage is a recognised side effect of some CAR-T therapies for cancer, and one that could be spotted early using a pen device developed by UK company Manus Neurodyna
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh